Home/Pipeline/SAN2668

SAN2668

Epilepsy

Phase 2Active (Licensed to Jazz Pharmaceuticals)

Key Facts

Indication

Epilepsy

Phase

Phase 2

Status

Active (Licensed to Jazz Pharmaceuticals)

Company

Saniona

About Saniona

Saniona is a Danish biotech pioneer with a core competency in ion channel modulation, a historically challenging drug target class. The company has built a robust discovery engine and a library of over 20,000 proprietary molecules, translating this platform into a clinical-stage pipeline focused on epilepsy and rare CNS disorders. A recent licensing agreement with Jazz Pharmaceuticals validates its approach and provides non-dilutive funding. The company's strategy is to advance its own programs while leveraging partnerships to maximize the value of its ion channel platform.

View full company profile

Therapeutic Areas

Epilepsy Central Nervous System (CNS) Disorders Rare Diseases Hypothalamic Obesity Prader-Willi Syndrome Major Depressive Disorder

Other Epilepsy Drugs

Drug	Company	Phase	Status
ADX71149 (mGlu2 PAM)	Addex Therapeutics	Phase 2	Active (with Janssen)
TRV045	Trevena	Phase 1	Active
SAGE-324	Sage Therapeutics	Preclinical	Research
Motpoly XR™	Aucta Pharmaceuticals	Not Specified (Likely Phase 3/NDA)	Active
ADB-104	Adolore BioTherapeutics	Pre-clinical	Active
Not Publicly Disclosed	Cerecin	Phase 2	Active
eTNS Platform	NeuroSigma	Unknown	Active
NPT 2042	NeuroPro Therapeutics	Phase 2	Active
Spritam (levetiracetam)	Aprecia Pharmaceuticals	Approved	Active
Perampanel	Ark Diagnostics	In Development	Active
NeuroAccess Platform	Cordance Medical	Pre-clinical/Research	Active
Epilepsy Program	Current Surgical	Research	Active